Explained: New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

The FDA approved a new mRNA-based flu vaccine called mFlusiva, made by Moderna, for adults age 50 and older

mRNA technology

The vaccine platform, key to ending the COVID-19 pandemic, now used in this new flu vaccine

Accelerated approval

A type of FDA approval granted for the 65+ age group based on smaller study data, while an additional study is conducted

Full approval

The type of FDA approval granted for the 50-64 age group based on a large study

High-dose vaccine

An existing flu vaccine for seniors that Moderna's shot was compared against for immune response in the 65+ study